Literature DB >> 7917203

Craniofacial resection. An analysis of 73 cases.

P J Catalano1, C S Hecht, H F Biller, W Lawson, K D Post, V Sachdev, C Sen, M L Urken.   

Abstract

OBJECTIVE: To determine the morbidity and mortality associated with a large series of patients undergoing craniofacial resection at one institution. The series is also analyzed with respect to pathology, disease recurrence, and role of adjuvant therapy.
DESIGN: Retrospective review with a mean follow-up of 3 years (range, 6 months to 8 years).
SETTING: Tertiary care, urban referral center. PATIENTS: The study included 73 consecutive patients (39 male and 34 female). Ages ranged from 13 to 78 years with a mean of 53.1 years. All patients had benign or malignant tumors of the paranasal sinuses. MAIN OUTCOME MEASURES: Morbidity associated with craniofacial resection was categorized as follows: early (within 30 days of surgery) or late (> 30 days); neurologic, ocular, or infectious.
RESULTS: Overall morbidity rate was 63%, and the mortality rate was 2.7%. Of the patients who had complications develop, 26 had development of major morbidities and there were two mortalities. The most common complications were transient alteration in mental status (15 patients), diplopia (11 patients), cerebrospinal fluid leak (10 patients), and osteomyelitis of the frontal bone flap (eight patients).
CONCLUSIONS: Craniofacial resection is an effective surgical treatment for paranasal sinus tumors. The mortality rate is acceptable and morbidity appears directly related to experience with the procedure. Infectious complications were the most devastating.

Entities:  

Mesh:

Year:  1994        PMID: 7917203     DOI: 10.1001/archotol.1994.01880350017004

Source DB:  PubMed          Journal:  Arch Otolaryngol Head Neck Surg        ISSN: 0886-4470


  13 in total

1.  Craniofacial resection for sinunasal tumors.

Authors:  M Granados-García; M A Celis-López; J L Aguilar-Ponce; V Villavicencio-Valencia; K Luna-Ortiz; A Poitevin-Chachón; F Carrillo-Hernández; A Herrera-Gómez
Journal:  Clin Transl Oncol       Date:  2006-02       Impact factor: 3.405

2.  Olfactory neuroblastomas: survival rate and prognostic factor.

Authors:  Sung-Kyun Hwang; Sun-Ha Paek; Dong Gyu Kim; Yoon-Kyung Jeon; Je G Chi; Hee-Won Jung
Journal:  J Neurooncol       Date:  2002-09       Impact factor: 4.130

3.  Sinonasal undifferentiated carcinoma: current trends in treatment.

Authors:  K T Pitman; P D Costantino; L F Lassen
Journal:  Skull Base Surg       Date:  1995

4.  Imaging central skull base neural tumor spread from paranasal sinus malignancies: a critical factor in treatment planning.

Authors:  P M Som; P D Costantino; A R Silvers
Journal:  Skull Base Surg       Date:  1999

Review 5.  Free-Flap Reconstruction of Skull Base and Orbital Defects.

Authors:  Weitao Wang; Aurora Vincent; Mofiyinfolu Sokoya; Scott Kohlert; Sameep Kadakia; Yadranko Ducic
Journal:  Semin Plast Surg       Date:  2019-03-08       Impact factor: 2.314

6.  Fibro-osseous lesions of the maxillo-ethmoid complex with orbital involvement.

Authors:  D Jha; S Bahadur; A Thakar; A Chava
Journal:  Indian J Otolaryngol Head Neck Surg       Date:  2001-07

Review 7.  Complications of Skull Base Surgery.

Authors:  Mofiyinfolu Sokoya; Moustafa Mourad; Yadranko Ducic
Journal:  Semin Plast Surg       Date:  2017-10-25       Impact factor: 2.314

8.  The treatment of advanced sinonasal malignancies with pre-operative intra-arterial cisplatin and concurrent radiation.

Authors:  L Madison Michael; Jeffrey M Sorenson; Sandeep Samant; Jon H Robertson
Journal:  J Neurooncol       Date:  2005-03       Impact factor: 4.130

9.  Anterior skull base surgery.

Authors:  Moni Abraham Kuriakose; Nirav P Trivedi; Vikram Kekatpure
Journal:  Indian J Surg Oncol       Date:  2010-11-21

Review 10.  Craniofacial resection for malignant tumours involving the anterior skull base.

Authors:  Giulio Cantù; Stefano Riccio; Gabriella Bimbi; Massimo Squadrelli; Sarah Colombo; Alvaro Compan; Marco Rossi; Madia Pompilio; Carlo L Solero
Journal:  Eur Arch Otorhinolaryngol       Date:  2006-03-15       Impact factor: 2.503

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.